US Market Expansion With Quanta's expansion in the United States and ongoing funding, target regional dialysis networks, hospital systems, and dialysis centers to accelerate adoption. Emphasize the Quanta Dialysis System's compact footprint, multi-therapy capability (IHD, SLED, CRRT) and performance comparable to larger machines, and propose pilot programs and bundled service arrangements to shorten procurement cycles.

Home Dialysis Growth Capitalize on FDA clearance for home hemodialysis and real‑world evidence from the Home Run study to target home dialysis programs, nephrology clinics, and home care agencies. Highlight ease of use, lack of bags, reduced training needs, and optional remote monitoring, and offer partnerships for patient training and ongoing support to scale home deployment.

Cost Efficiency Position Quanta as a cost‑efficient option that reduces consumables, logistics, and maintenance downtime due to its bagless design and once‑weekly rinse. Provide ROI and total cost of ownership analyses to payers and procurement teams, and reference early deployment data to strengthen the business case.

Multi-Setting Value Promote the device as a single solution capable of IHD, SLED, and CRRT across hospital, ICU, and home settings to help health systems consolidate equipment and simplify workflows. Target procurement conversations with nephrology, critical care, and supply‑chain stakeholders and propose cross‑department deployment plans.

Credibility and Partnerships Leverage engineering prestige and regulatory milestones, including the MacRobert Award and FDA clearances, plus recent Series E funding, to build credibility with buyers. Pursue strategic partnerships with dialysis networks, distributors, and tandem care providers, and collaborate on joint pilots and evidence generation to accelerate adoption.